RadNet (NASDAQ:RDNT) Announces Earnings Results

RadNet (NASDAQ:RDNT) issued its quarterly earnings data on Monday. The medical research company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.04, FiscalAI reports. The company had revenue of $547.71 million during the quarter, compared to the consensus estimate of $515.67 million. RadNet had a negative net margin of 0.91% and a positive return on equity of 2.60%. RadNet’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter last year, the company earned $0.22 earnings per share.

Here are the key takeaways from RadNet’s conference call:

• Record Q4 and 2025 results: Total revenue rose 14.8% to $547.7M and Adjusted EBITDA increased 16.9% to $87.7M, with year-end cash of roughly $776M and net debt/Adjusted EBITDA around 1.0x.
• Completed acquisition of Gleamer: RadNet closed the Paris-based AI vendor deal (up to €230M), adding ~700 customer contracts and an expected ~ $30M ARR contribution that DeepHealth says will make it the largest provider of radiology clinical AI worldwide.
• Aggressive 2026 growth targets and ARR ambition: Company guided imaging center revenue +17%–19% and Digital Health +45%–55% for 2026, and expects Digital Health ARR to approach or exceed ~$140M by year-end 2026.
• Near-term margin and cash pressures: Management embeds roughly $30M of same‑center labor cost increases, first‑quarter weather headwinds, and expects Gleamer to be EBITDA‑negative in 2026 (company cited up to ~$5M drag), with pro forma leverage rising to ~1.6–1.8x after recent deals.
• Operational expansion and AI rollout: RadNet opened seven de novo centers in 2025, plans 11–13 new centers in 2026, continues JV growth with health systems (151 of 418 centers partnered), and plans to deploy AI (triage, draft reporting, TechLive) to drive productivity and cross‑sell DeepHealth solutions.

RadNet Stock Performance

Shares of RDNT stock opened at $72.58 on Wednesday. The stock has a market capitalization of $5.60 billion, a price-to-earnings ratio of -290.32 and a beta of 1.49. RadNet has a one year low of $45.00 and a one year high of $85.84. The company’s 50-day simple moving average is $71.67 and its 200-day simple moving average is $74.45. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.87 and a current ratio of 1.87.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Danske Bank A S bought a new stake in shares of RadNet in the 3rd quarter valued at approximately $30,000. Allworth Financial LP boosted its holdings in RadNet by 346.6% in the third quarter. Allworth Financial LP now owns 393 shares of the medical research company’s stock worth $30,000 after purchasing an additional 305 shares during the period. State of Wyoming bought a new stake in RadNet during the second quarter valued at $58,000. Kestra Advisory Services LLC acquired a new stake in shares of RadNet during the fourth quarter worth $67,000. Finally, Jones Financial Companies Lllp lifted its position in shares of RadNet by 563.4% in the 1st quarter. Jones Financial Companies Lllp now owns 1,705 shares of the medical research company’s stock worth $85,000 after buying an additional 1,448 shares during the last quarter. Institutional investors own 77.90% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on RDNT shares. The Goldman Sachs Group raised shares of RadNet to a “buy” rating in a report on Tuesday, December 16th. Raymond James Financial reissued a “strong-buy” rating on shares of RadNet in a research report on Thursday, December 18th. Zacks Research lowered RadNet from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 12th. B. Riley Financial increased their price target on RadNet from $71.00 to $87.00 and gave the company a “buy” rating in a report on Monday, December 1st. Finally, KeyCorp upgraded RadNet to a “strong-buy” rating in a research note on Friday, January 9th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $90.43.

About RadNet

RadNet, Inc is a leading independent provider of outpatient diagnostic imaging services in the United States. Through a nationwide network of fixed-site imaging centers and affiliated joint-venture locations, the company delivers a comprehensive suite of radiology services including MRI, CT, PET/CT, ultrasound, X-ray, mammography, bone densitometry, nuclear medicine and interventional radiology procedures. RadNet also offers teleradiology and imaging management solutions to physician practices, hospitals and healthcare systems.

Founded in 1981 and headquartered in Los Angeles, RadNet has expanded its footprint organically and through strategic acquisitions.